Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 24

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 24
---
 development requirements of product candidates that we may pursue; |

| • |     | the timing and amount of the milestone, royalty or other payments we must make to Sanofi SA (“Sanofi”), the 
 Cystic Fibrosis Foundation (“CFF”), AbbVie Global Enterprises Ltd. (“AbbVie”) and any other third parties;  |

| • |     | the costs, timing and outcome of regulatory review of our product candidates; |

| • |     | our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial 
 infrastructure;                                                                                                             |

| • |     | the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and 
 distribution, for any of our product candidates for which we receive marketing approval;                           |

| • |     | the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual 
 property rights and defending any intellectual property-related claims;                                                   |

| • |     | our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors (or                                         
 patients’ willingness to pay out-of-pocket for any approved products in the absence of such coverage) and adequate market share and revenue for any approved 
 products;                                                                                                                                                    |

| • |     | the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval; |

19

| • |     | the effect of macroeconomic trends including inflation and interest rates; |

| • |     | addressing any potential supply chain interruptions or delays; and |

| • |     | the costs of operating as a public company. |

We will require additional capital to achieve our business objectives. Additional funds may not be available on a timely basis, on favorable terms or at all, and such funds, if raised, may not be sufficient to enable us to continue implementing our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by potentially worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States (“U.S.”) and worldwide resulting from factors that include but are not limited to, inflation, the Russia-Ukraine and Israel-Gazaconflicts, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, uncertainty about economic stability and other factors. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and more dilutive